

Duodenal Ulcer in Osteoarthritis Patient Using Non Steroidal Anti Inflammatory Drugs

I Gede Komang Aditya Permana

General Practitioner, Wangaya General Hospital, Denpasar, Bali, Indonesia

Abstract: 68-year-old female Javanese tribe comes with a major complaint of melena and pain in the epigastric area. Patients often consume nsaid as a pain reliever on their knees, because patients have been diagnosed with osteoarthritis. The patient came pale and weak, on the laboratory examination patients get a severe anemia. Esofagogastrroduodenoscopy then performed on this patient and obtained a picture of ulcers on the duodenum. Transfusions and Proton Pump Inhibitor medication are administered to treat the patient's condition, NSAID medications are temporarily not given.

Keywords: duodenal ulcer, nsaid, osteoarthritis

1. Introduction

Osteoarthritis is an inflammatory disease that attacks the joint cartilage and subcondral bone, associated with genetic factors, biomechanical and biochemical changes in joint cartilage.[1]Risk factors include advancing age, trauma, genetics, female sex, and obesity. Disability in activities of daily living can happen because joint pain usually worsened by movement.[2]Disease that have symptom of musculoskeletal pain, like Osteoarthritis, NSAIDs are commonly used because of their effect as analgesic and anti-inflammatory. ACR in 2012 recommends if the patient doesn't have a satisfactory response with analgesic acetaminophen full dose, they recommend the use of oral NSAIDs or topical or intraarticular corticosteroid injection. [3,4] Furthermore ACR recommend using COX 2 selective NSAIDs or combination of NSAIDs and PPI in patient with GI ulcer

Mechanism of action of NSAIDs was by inhibition of Prostaglandin synthesis, through inhibition and binding of enzyme cyclooxygenase (COX) including two isoform COX-1 and COX-2 [5]NSAIDs are a leading cause of drug-related morbidity, especially in the elderly and patients with comorbidities.[6]Renal problem, cardiovascular and hepatic injury was either adverse event of using NSAIDs, however, the most important and common adverse effects of NSAIDs are the gastrointestinal (GI) adverse effects. The adverse events of this drug can cause new problems besides the pain problem that the patient is experiencing. The extensive use of NSAIDs in prescriptions and by over the counter NSAID users has made GI complications a severe problem, because the patient can easily use it without precaution.[7]Gastrointestinal adverse event that usually happen is bleeding including gastric or duodenal ulcer or both at the same time, and to a lesser extent obstructions and/or perforations.[8,9]

2. Case report

A 68-year-old female Javanese tribe was admitted to the hospital with chief complaint melanic stool since 7 days prior admission. She also felt abdominal pain or discomfort in epigastric area since 5 days prior admission, mostly when she eats some food she feels the symptom a little relieved

and she felt weak since 5 days ago that worsen prior to admission. She also found it difficult to walk because of the pain and stiffness she experienced on both knee since about 3 years ago that worsen from about 6 month ago, history of accident and trauma was denied by patient, she had previously been diagnosed with osteoarthritis. The patient reported being prescribed piroxicam 20 mg daily as needed for the pain by her primary health care, and patient usually buys analgetics over the counter by herself if the pain doesn't improve. Reported the patient from 6 month ago usually feeling epigastric pain and the symptom relieved when she consume antacida, no personal or family history of gastric ulcer, no diabetes mellitus, hypertension, hepatic and cardiovascular problem. On examination, the patient looks lethargic and pale in the conjunctiva, with blood pressure of 120/80 mmHg, heart rate of 100 beats per minute. On abdominal examination we found tenderness in epigastric area if palpated. Extremities examination, on left and right knee there was no deformation, feel warm on palpation, crepitation and there was decreased range of motion. Hemoglobin was 5.8 g/dL and hematocrit was 18.5%; BUN 41, creatinine serum 0.7, all other evaluated laboratory values were within normal limits. Using modified Glasgow blacthford the score was 12 indicating that endoscopy needed in this patient. Endoscopy revealed ulcer in the pars 1 of duodenum with forrest 3 classification.



Figure 1: Duodenal ulcer in the pars 1 duodenum

Volume 7 Issue 7, July 2018

www.ijsr.net

Licensed Under Creative Commons Attribution CC BY

Biopsies was not performed because the patient refuse it.. The patient was treated with an intravenous proton-pump inhibitor (PPI) bolus of 80mg initially then twice daily, given blood transfusion and remained hospitalized for observation and to evaluate for rebleeding, NSAID medications are temporarily not given. After 7 days without evidence of rebleeding, with the patient hemoglobin reaches ≥ 10 g/dL, and stable vital sign, she was then discharged home with an oral PPI.

3. Discussion

Peptic ulcer disease is a problem of the gastrointestinal tract characterized by mucosal damage secondary to pepsin and gastric acid secretion. It usually occurs in the stomach and proximal duodenum; less commonly, it occurs in the lower esophagus, the distal duodenum, or the jejunum. Lifetime prevalence of peptic ulcer disease in the general population has been estimated to be about 5–10%, and incidence 0.1–0.3% per year.[10] In the United States approximately 500,000 persons develop peptic ulcer disease each year.[11] In 70 percent of patients it occurs between the ages of 25 and 64 years.[12]

Peptic ulcer disease symptoms include episodic epigastric pain either burning or gnawing; pain occurring after meals or on an empty stomach; and nocturnal pain relieved by food intake, antacids, or antisecretory agents. The most specific symptoms like a history of episodic or epigastric pain, relief of pain after food intake, and nighttime awakening because of pain with relief following food intake can help rule in the diagnosis.[13] Loss of appetite, indigestion, heartburn, intolerance of fatty foods, a positive family history and vomiting, was some less common symptoms.[13] The physical examination was not very helpful in one study, tenderness to deep palpation reduced the likelihood of ulcer. [13] Postprandial epigastric pain that relieved by food or antacids is more likely to be in patients with duodenal ulcers than in those with gastric ulcers.

If the initial clinical presentation suggests the diagnosis of peptic ulcer disease, the patient should be evaluated for alarm symptoms. Anemia, hematemesis, melena, or hemepositive stool, continuous vomiting, anorexia or weight loss, persisting upper abdominal pain radiating to the back, and severe, spreading upper abdominal pain was some of the alarm symptoms. Patients older than 55 years and those with alarm symptoms should be referred for prompt upper endoscopy. Esophagogastroduodenoscopy (EGD) is more sensitive and specific for peptic ulcer disease and allows biopsy of gastric lesions.[14]. Symptoms in these patients have led to duodenum ulcers. EGD examination which will then be done is appropriate, because the patient's age is more than 55 years ie 68 years, and alarm symptoms have been found in this patient that is anemia and melena. Results from esophagogastroduodenoscopy then indicate this patient has duodenal ulcer in pars 1 duodenum with Forrest 3 classification.

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) are the major causes of peptic ulcer disease.[15] Other factors including H. Pylori infection, medication like steroid, bisphosphonates, potassium chloride, chemotherapeutic

agents (e.g., intravenous fluorouracil), rare condition like Acid-hypersecretory states (e.g., Zollinger-Ellison syndrome), Malignancy (Gastric cancer, lymphomas, lung cancers), Stress (After acute illness, multiorgan failure, ventilator support, extensive burns (Curling's ulcer), or head injury (Cushing's ulcer) can also contribute to gastroduodenal ulcers.[16] NSAIDs users compared with non-users, NSAID use can increase the risk of complications of peptic ulcer disease by four times.[15,17]

Main mechanism of the gastroduodenal damage that caused by NSAIDs is through systemic inhibition of cyclooxygenase 1 (COX-1) that cause reduced prostaglandin. Reduced mucosal prostaglandin values are associated with decreased mucosal blood flow, low mucus and bicarbonate secretion, inhibition of cell proliferation, which are essential to maintenance of mucosal integrity. Studies showing that coadministration exogenous prostaglandins can reduce mucosal damage supporting the COX hypothesis. [18] However, this hypothesis does not fully explain the spectrum of mucosal damage. People taking NSAIDs could have a decrease in mucosal prostaglandins without developing gastric lesions.[19,20,21] The other mechanism NSAID initiate mucosal damage in the cell is through disruption of mucus phospholipids or the cell membrane and by uncoupling of mitochondrial oxidative phosphorylation. The loss of mucosal integrity is followed by tissue reaction amplified by luminal content such as acid, pepsin, food, bile, and *H. pylori*. [20,21] NSAIDs can cause local injuries via trapping theory, in gastric juice NSAIDs are lipid soluble and non-ionized, these NSAIDs then diffuse across gastric mucosa epithelial cell membranes to the cytoplasm, where the pH is neutral. In neutral pH NSAIDs are converted into the re-ionized and relatively lipophobic form. Therefore, NSAIDs are trapped and accumulate within cells leading to cellular injury. [22]




Figure 2: Mechanism NSAIDs induce gastrointestinal damage.[23]

Different NSAIDs have different upper-GI risks. In a systematic review and meta-analysis of observational studies, different NSAIDs, including COX2 inhibitors, showed different risks of upper-GI complications.[24] The NSAIDs with the lowest relative risk included celecoxib and ibuprofen, while piroxicam had one of the highest. Based on studies have proven that non-selective NSAIDs especially piroxicam is one of the factors that influence the incidence of duodenal ulcer in this patient. It is also possible that the ulcer in this patient is also caused by the use of NSAIDs in conjunction with H. pylori infection because the patient refuses to do the biopsy.

Treatment for the acute non-variceal upper GI bleeding should be started empirically with an acid suppression medication, suggested intravenous PPI, eg esomeprazole 40mg twice daily after an initial bolus of 80mg intravenous. PPI may also promote hemostasis in patients with lesion other than ulcer, this maybe occurs because neutralization of gastric acid leads to the blood clots stabilization.[25].

ACR recommends If the patient has a history of asymptomatic or complicated upper GI ulcer but in the past year has no had an upper GI bleed and the practitioner chooses to use an oral NSAID, ACR strongly recommends using either a cyclooxygenase 2 (COX-2) selective inhibitor or a nonselective NSAID in combination with a proton-pump inhibitor[26] If the patient has had an upper GI bleed within the past year and the practitioner still chooses to use an oral NSAID, the ACR recommends using a COX-2 selective inhibitor in combination with a proton-pump inhibitor. Therefore, for the chronic management of patients with knee or hip OA, the practitioners should consider adding a proton-pump inhibitor when chooses NSAIDs oral as the treatment to reduce the risk of development of symptomatic or complicated upper GI events.[27]

American College of Gastroenterology in guidelines on management of bleeding Ulcers also stated that In patients with NSAID-associated bleeding ulcers whomust resume NSAIDs, it is recommended to give a daily PPI together with a COX2-selective NSAID at the lowest effective dose.[27] In patients with low-dose aspirin-associated bleeding ulcers that have been resumed on aspirin for secondary prevention, long-term daily PPI therapy should also be provided.[28]. In these patients we did not continue with nsaid administration because we chose to use topical nsaid and nonpharmacologic therapy given the age of the patients who were too old and the side effects that had occurred.

4. Conclusion

This case report discusses a 68-year-old woman with duodenal ulcer caused by long-term use of NSAIDs due to her osteoarthritis disease, h pylori infection still can not be excluded because the patient refused to do biopsy. As a doctor we should consider the therapy to be given, given the side effects of NSAIDs very often found in the gastrointestinal tract. May be considered non-pharmacological therapy and the use of a selective nsaid or nsaid use in combination with ppi in patients that we have to administer analgesics.

Reference

- [1] Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. *J Bone Joint Surg Am* 1971; 53:523.
- [2] Keith Sinusas, MD, Middlesex Hospital, Middletown, Connecticut *Am Fam Physician*. 2012 Jan 1;85(1):49-56. OA diagnosis and treatment)
- [3] American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal

- Antiinflammatory Drugs. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. *Arthritis Rheum* 2008;59:1058-73.
- [4] Chou R, Helfand M, Peterson K, Dana T, Roberts C. Comparative effectiveness and safety of analgesics for osteoarthritis: comparative effectiveness review no. 4. Rockville (MD): Agency for Healthcare Research and Quality; 2006. URL: www.effectivehealthcare.ahrq.gov/reports/final.cfm.
- [5] Crofford L: Prostanoid biology and its therapeutic targeting. In *Kelley's Textbook of Rheumatology*. Edited by Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR. 9th edition. Philadelphia: Saunders; 2013:871-893.
- [6] Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. *Eur J Clin Pharmacol*. 2014;70(10):1159-1172.
- [7] Wang X. Aspirin-like drugs cause gastrointestinal injuries by metal cation chelation. *Med Hypotheses*. 1998;50(3):227-238.
- [8] Lazzaroni M, Porro GB. Management of NSAID-induced gastrointestinal toxicity. *Drugs*. 2009;69(1):51-69.
- [9] Butt JH, Barthel JS, Moore RA. Clinical spectrum of the upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs: natural history, symptomatology, and significance. *Am J Med*. 1988;84(2):5-14.
- [10] Del Valle J. Peptic ulcer disease and related disorders. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J, eds. *Harrison's Principles of Internal Medicine* (19th edn). New York, NY: McGraw Hill Education, 2015: 1911-32.
- [11] Ramakrishnan. Salinas, RC. *Peptic Ulcer Disease*. American Family Physician. Volume 76, Number 7 2007
- [12] Sonnenberg A, Everhart JE. The prevalence of self-reported peptic ulcer in the United States. *Am J Public Health* 1996;86:200-5.
- [13] Spiegelhalter DJ, Crean GP, Holden R, Knill-Jones RP. Taking a calculated risk: predictive scoring systems in dyspepsia. *Scand J Gastroenterol Suppl* 1987;128:152-60.
- [14] Talley NJ, Vakil NB, Moayyedi P. American Gastroenterological Association technical review on the evaluation of dyspepsia. *Gastroenterology* 2005;129:1756-80.
- [15] Lanas A, Carrera-Lasfuentes P, Arguedas Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. *Clin Gastroenterol Hepatol* 2015; 13: 906-12.
- [16] Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal anti-inflammatory drugs, *Helicobacter pylori*, and smoking. *J Clin Gastroenterol* 1997;24:2-17.
- [17] Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-

- aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. *Gut* 2006; **55**: 1731–38.
- [18] Silverstein FE, Graham GY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. *Ann Int Med* 1995; **123**: 241–49.
- [19] Bjarnason I, Scarpignato C, Takeuchi K, Rainsford KD. Determinants of the short-term gastric damage caused by NSAIDs in man. *Aliment Pharmacol Ther* 2007; **26**: 95–106.
- [20] Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. *Gastroenterology* 1997; **112**: 1000–16.
- [21] Lanas A, Panés J, Piqué JM. Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. *Curr Pharm Des* 2003; **9**: 2253–66.
- [22] Laine, L., 1996. Nonsteroidal anti-inflammatory drug gastropathy. *Gastrointestinal endoscopy clinics of North America*, 6(3), pp.489-504.
- [23] Sinha, M., Gautam, L., Shukla, P.K., Kaur, P., Sharma, S. and Singh, T.P., 2013. Current perspectives in NSAID-induced gastropathy. *Mediators of inflammation*, 2013.
- [24] Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications. *Drug Saf*. 2012;35(12):1127–1146.
- [25] Saltzman, J.R., Feldman, M. and Travis, A., 2015. Approach to acute upper gastrointestinal bleeding in adults. *UpToDate, Waltham, MA*. (Accessed on June 25, 2018.).
- [26] Rostom A, Muir K, Dube C, Lanas A, Jolicoeur E, Tugwell P. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. *Drug Healthc Patient Saf* 2009;1:47–71.
- [27] Hochberg, MC. Altman, RD. April, K et al. American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee. *Arthritis Care & Research* Vol. 64, No. 4, April 2012, pp 465–474
- [28] Laine L, Jensen DM. Management of patients with ulcer bleeding. *Am J Gastroenterol*. 2012;107(3):345–361.